Peptron has stated, regarding the anti-obesity efficacy trial of its long-acting obesity treatment, that "the dosing interval applied in animal experiments should not be interpreted as the maximum duration of the drug." The company explained that the results of dosing at two-week intervals confirmed in mouse experiments do not represent the limit of the drug's efficacy duration applicable to humans.

The stock closed lower. On the 22nd in the KOSDAQ market, Peptron (087010) finished trading at 100,900 won in the aftermarket, down 4,700 won (4.45%) from the previous trading day.

■ Trial Conducted on Diet-Induced Obese (DIO) Mice... Dosing at Intervals of Up to Two Weeks

Peptron explained that the anti-obesity efficacy trial described in the patent specification was conducted on mice in which obesity was induced by a high-fat diet (DIO mice). In that trial, the company administered its long-acting formulation at intervals of up to two weeks to confirm anti-obesity efficacy.

■ "Dosing Interval ≠ Maximum Drug Duration, They Must Be Distinguished"

What the company emphasized is that the dosing interval applied in the trial and the maximum duration of the drug must be distinguished. The fact that efficacy was confirmed when dosed at two-week intervals alone does not mean that the drug's effect disappears after two weeks.

However, the results alone also cannot be taken as proof that the drug's efficacy duration exceeds two weeks.

■ Pharmacokinetic Differences Between Animals and Humans Must Also Be Considered

Peptron explained that pharmacokinetic differences between animals and humans must also be taken into account. Pharmacokinetics refers to the process by which a drug is absorbed, distributed, metabolized, and excreted in the body.

[This article is provided for informational purposes to aid investment decisions and does not recommend the purchase or sale of any specific stock. Content is subject to change depending on market conditions. Investment decisions and any resulting responsibility lie with the investor. AI provided partial assistance.]